Potential of bone morphogenetic protein-7 in treatment of lupus nephritis: addressing the hurdles to implementation

Up to 50% of systemic lupus erythematosus (SLE) patients world-wide develop lupus nephritis (LN). In low to middle income countries and in particular in sub-Saharan Africa, where SLE is prevalent with a more aggressive course, LN and end stage renal disease is a major cause of mortality. While devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Carine, du Toit, Riette, Ollewagen, Tracey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518293/
https://www.ncbi.nlm.nih.gov/pubmed/37626268
http://dx.doi.org/10.1007/s10787-023-01321-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518293/
https://www.ncbi.nlm.nih.gov/pubmed/37626268
http://dx.doi.org/10.1007/s10787-023-01321-x

Ejemplares similares